๎๊ฒ์
๎๊ฒ์
๎
Transcode Therapeutics Inc
RNAZ๎ญ๊ด์ฌ ๋ชฉ๋ก์ ์ถ๊ฐ
6.600USD
-0.280-3.95%
์ข
๊ฐย 05/15, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
6.05M์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ Transcode Therapeutics Inc ํ์ฌ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ RNAZ
ํ์ฌ ์ด๋ฆTranscode Therapeutics Inc
์์ฅ์ผApr 28, 2021
CEOCalais (Philippe P)
์ง์ ์7
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃApr 28
์ฃผ์6 Liberty Square
๋์BOSTON
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ02109
์ ํ18573016857
์น์ฌ์ดํธhttps://www.transcodetherapeutics.com/
์ข
๋ชฉ ์ฝ๋ RNAZ
์์ฅ์ผApr 28, 2021
CEOCalais (Philippe P)
Transcode Therapeutics Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
+33.33%
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
+50.00%
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
+33.33%
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
+50.00%
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
์์ต ๋ถ์
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, May 14
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, May 14
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
Geode Capital Management, L.L.C.
1.20%
UBS Financial Services, Inc.
0.90%
Vanguard Capital Management, LLC
0.71%
๊ธฐํ
83.57%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
Geode Capital Management, L.L.C.
1.20%
UBS Financial Services, Inc.
0.90%
Vanguard Capital Management, LLC
0.71%
๊ธฐํ
83.57%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Corporation
9.08%
Investment Advisor/Hedge Fund
5.73%
Investment Advisor
2.66%
Individual Investor
0.14%
Hedge Fund
0.10%
๊ธฐํ
82.29%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Apr 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Apr 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2026Q1
37
77.85K
8.49%
-42.31K
2025Q4
36
70.82K
7.72%
-29.38K
2025Q3
37
40.93K
4.61%
-48.04K
2025Q2
41
77.84K
18.97%
+69.48K
2025Q1
45
80.09K
9.69%
+74.47K
2024Q4
36
155.76K
22.37%
+143.23K
2024Q3
40
10.06K
1.97%
-8.53K
2024Q2
41
8.22K
4.45%
-5.03K
2024Q1
41
12.92K
7.67%
+11.92K
2023Q4
41
826.00
4.24%
+40.00
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
CK Life Sciences International Holdings, Inc.
83.28K
9.08%
+83.28K
--
Oct 27, 2025
Sabby Management, LLC
41.60K
4.54%
+41.60K
--
Dec 31, 2025
Geode Capital Management, L.L.C.
5.27K
0.58%
--
--
Jan 31, 2026
UBS Financial Services, Inc.
2.96K
0.32%
+2.96K
--
Dec 31, 2025
The Vanguard Group, Inc.
6.54K
0.71%
--
--
Feb 28, 2026
Tracy (Thomas Joseph)
1.25K
0.14%
+1.25K
--
Mar 07, 2025
Tower Research Capital LLC
887.00
0.1%
+745.00
+524.65%
Dec 31, 2025
SBI Securities Co., Ltd.
10.00
0%
--
--
Dec 31, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎์ด๋ฆ
๋น์จ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
Apr 16, 2025
Merger
28โ1
Nov 25, 2024
Merger
33โ1
Nov 25, 2024
Merger
33โ1
Nov 25, 2024
Merger
33โ1
Nov 25, 2024
Merger
33โ1
Jan 11, 2024
Merger
40โ1
๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
Apr 16, 2025
Merger
28โ1
Nov 25, 2024
Merger
33โ1
Nov 25, 2024
Merger
33โ1
Nov 25, 2024
Merger
33โ1
Nov 25, 2024
Merger
33โ1
Jan 11, 2024
Merger
40โ1
Jan 11, 2024
Merger
40โ1
Jan 11, 2024
Merger
40โ1
Jan 11, 2024
Merger
40โ1
May 22, 2023
Merger
20โ1
๋ ๋ณด๊ธฐ
